The Patient Tearing Up My Waiting Room Is Why Cebranopadol Matters
Tris Pharma presents cebranopadol (TRN-228) dual NOP/MOP data at CPDD 2026. For patients with comorbid chronic pain and OUD,...
Tris Pharma presents cebranopadol (TRN-228) dual NOP/MOP data at CPDD 2026. For patients with comorbid chronic pain and OUD,...
A Lancet Psychiatry network meta-analysis of ADHD pharmacotherapy exposes therapeutic inertia and uncritical dose escalation as twin hazards—with direct…
New Cell data pinpoints intratelencephalic neurons in the anterior insula as the mechanistic key to aiTBS antidepressant effects—here's what...
Auvelity's FDA expansion into Alzheimer's agitation—peak sales now projected at $8B—exposes how long antipsychotics dominated a space where safer...
A Lancet RCT shows once-weekly semaglutide cut heavy drinking days in obese AUD patients — targeting a condition where...
CREST–MST in Lancet Psychiatry shows magnetic seizure therapy matches ECT remission rates with superior cognitive safety—reshaping convulsive therapy trial…
The CREST-MST trial in Lancet Psychiatry shows magnetic seizure therapy matches ECT remission rates in TRD with a superior...
France's March 2026 approval of intravenous racemic ketamine for severe suicidal crisis is the first regulatory action of its...
Lipocine's LPCN 1154 just failed its Phase 3 trial for postpartum depression, sending shares down 77%. For psychiatrists treating...
A pattern I’ve been tracking across my dual-diagnosis patient panel this year: the patients who come in asking about...